Ovid Therapeutics Inc.
OVID Nasdaq
SEC CIK 1636651
Follow Ovid Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$20.8M
−70.9% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$15.9M
−23.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $7.3M | −$17.4M |
| FY24 | $566K | −$26.4M |
| FY23 | $392K | −$52.3M |
| FY22 | $1.5M | −$54.2M |
| FY21 | $208.4M | $122.8M |
| FY20 | $12.6M | −$81M |
| FY19 | - | −$60.5M |
| FY18 | - | −$52M |
| FY17 | - | −$64.8M |
| FY16 | - | −$22.4M |
| FY15 | - | −$13.2M |
| FY14 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −585.2% | −239.9% |
| FY24 | −10933.7% | −4664.3% |
| FY23 | −15122.7% | −13341.8% |
| FY22 | −3696.4% | −3604.7% |
| FY21 | 59.6% | 58.9% |
| FY20 | −645.4% | −642.3% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$38.3M |
| FY24 | −$56M |
| FY23 | −$45.8M |
| FY22 | −$56.5M |
| FY21 | $118.4M |
| FY20 | −$51.7M |
| FY19 | −$51.1M |
| FY18 | −$45.6M |
| FY17 | −$31.5M |
| FY16 | −$17.8M |
| FY15 | −$5.5M |
| FY14 | - |
- Ovid Therapeutics
- Healthcare median
Show the numbers
| Year | Ovid Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −239.9% | −30.6% |
| FY24 | −4664.3% | −47% |
| FY23 | −13341.8% | −58% |
| FY22 | −3604.7% | −80.4% |
| FY21 | 58.9% | −71.8% |
| FY20 | −642.3% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |